Objective To evaluate the efficacy of cytokine-induced killer(CIK),three-dimensional conformal radiotherapy(3D-CRT)and transcatheter arterial chemoembolization(TACE)in the treatment of patients with primary liver cancer(PLC). Methods 51 patients with PLC were randomly divided into combination group(n=26),receiving TACE/3D-CRT/CIK therapy,and control(n=25),receiving TACE/3D-CRT therapy. Results At the end of one month therapy,the percentage of CD3+,CD4+,CD16+CD56+and CD4+/CD8+ratio in the combination group were(66.47±1.25)%,(56.98±2.65)%,(22.45±6.41)% and(1.52 ±2.10),significantly higher than[(53.17± 0.98)%,(48.09±0.27)%,(19.74±1.88)% and(1.13±0.06),P<0.05],while that of CD8+cells was(37.56±1.26)%, much lower than [(42.67 ±4.35)%,P<0.05]in the control;the improvement rate of life quality in combination group was 84.6%,significantly higher than that in the control group(52.0%,P<0.05);the objective effective rate in the combination group was 92.3%,significantly higher than that in the control group(68.0%,P<0.05);the 1-year survival rate in the combination group was 73.1%,significantly higher than that in the control group(52.1%,P<0.05). Conclusion CIK cells combined radiotherapy and TACE for patients with PLC could improve the immune function,and patients' quality of life,which might lead to a good short-term efficacy and prolong the survival.%目的 评价细胞因子诱导的杀伤细胞(CIK)联合三维适形放疗和肝动脉化疗栓塞术(TACE)治疗原发性肝癌(PLC)患者的疗效.方法 将51例PLC患者随机分为治疗组26例和对照组25例,分别接受三维适形放疗/TACE和CIK细胞回输或只接受三维适形放疗和TACE治疗.结果 治疗组接受CIK细胞治疗后1月,外周血CD3+、CD4+、CD16+CD56+细胞百分比和CD4+/CD8+比值分别为(66.47±1.25)%、(56.98±2.65)%、(22.45±6.41)%和(1.52±2.10),显著高于对照组的[(53.17±0.98)%、(48.09±0.27)%、(19.74±1.88)%和(1.13±0.06),P<0.05],而CD8+细胞百分比为(37.56±1.26)%,显著低于对照组的[(42.67±4.35)%,P<0.05];治疗组生活质量改善率为84.6%,显著高于对照组的52.0%(P<0.05);治疗组客观有效率为92.3%,显著高于对照组的68.0%(P<0.05);治疗组1 a生存率为73.1%,显著高于对照组的52.1%(P<0.05).结论 CIK细胞联合放疗和TACE治疗可以提高PLC患者的免疫功能,改善患者生活质量,提高近期疗效,延长生存期.
展开▼
